ARGX Overview
Upcoming Projects (ARGX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ARGX)
-
II: Discussing physician perspectives on the clinical positioning and market differentiation of J&J’s newly approved Imaavy (nipocalimab) for generalized myasthenia gravis, in the context of competitors like Vyvgart, Rystiggo, and Zilbrysq
Tickers: JNJ, ARGX, UCBJY
Executed On: Jun 04, 2025 at 03:00 PM EDT -
Second View: Discussing Argenx's long term data for VYVGART presented at the at the American Academy of Neurology 2025 Annual Meeting.
Ticker: ARGX
Executed On: May 28, 2025 at 04:00 PM EDT -
Discussing physician perspectives on the clinical positioning and market differentiation of J&J’s newly approved Imaavy (nipocalimab) for generalized myasthenia gravis, in the context of competitors like Vyvgart, Rystiggo, and Zilbrysq
Tickers: JNJ, ARGX, UCBJY
Executed On: May 15, 2025 at 05:00 PM EDT -
Discussing Argenx's long term data for VYVGART presented at the at the American Academy of Neurology 2025 Annual Meeting.
Ticker: ARGX
Executed On: May 01, 2025 at 05:00 PM EDT -
A Second View: Digging into the Phase 3 ADHERE clinical trial data for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with CIDP
Ticker: ARGX
Executed On: May 06, 2024 at 06:00 PM EDT -
Digging into the Phase 3 ADHERE clinical trial data for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with CIDP
Ticker: ARGX
Executed On: Apr 24, 2024 at 06:00 PM EDT -
A Second Perspective: Looking into the data behind the FDA approval for Vyvgart Hytrulo (efgartigimod) in patients with generalized Myasthenia Gravis.
Ticker: ARGX
Executed On: Oct 04, 2023 at 02:00 PM EDT -
Looking into the data behind the FDA approval for Vyvgart Hytrulo (efgartigimod) in patients with generalized Myasthenia Gravis.
Ticker: ARGX
Executed On: Aug 14, 2023 at 05:00 PM EDT -
Third opinion: Checking on the Launch and market potential of Vyvgart in Treating Generalized Myasthenia Gravis
Ticker: ARGX
Executed On: May 27, 2022 at 05:00 PM EDT -
Second opinion: Checking on the Launch and market potential of Vyvgart in Treating Generalized Myasthenia Gravis
Ticker: ARGX
Executed On: May 26, 2022 at 07:00 PM EDT -
Checking on the Launch and market potential of Vyvgart in Treating Generalized Myasthenia Gravis
Ticker: ARGX
Executed On: May 26, 2022 at 04:00 PM EDT -
Discussing the standard of care and the potential of Vyvgart (efgartigimod alfa-fcab), the recently approved agent from Argenx in treating Myasthenia Gravis
Ticker: ARGX
Executed On: Feb 23, 2022 at 05:00 PM EST
Upcoming & Overdue Catalysts (ARGX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ARGX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
